The Structure-property Relationships of Clinically Approved Protease Inhibitors
Author:
- 1 April 2024
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 31 (12) , 1441-1463
Abstract
Background: Proteases play important roles in the regulation of many physiological processes, and protease inhibitors have become one of the important drug classes. Especially because the development of protease inhibitors often starts from a substrate- based peptidomimetic strategy, many of the initial lead compounds suffer from pharmacokinetic liabilities. Objective: To reduce drug attrition rates, drug metabolism and pharmacokinetics studies are fully integrated into modern drug discovery research, and the structure-property relationship illustrates how the modification of the chemical structure influences the pharmacokinetic and toxicological properties of drug compounds. Understanding the structure- property relationships of clinically approved protease inhibitor drugs and their analogues could provide useful information on the lead-to-candidate optimization strategies. Methods: About 70 inhibitors against human or pathogenic viral proteases have been approved until the end of 2021. In this review, 17 inhibitors are chosen for the structure- property relationship analysis because detailed pharmacological and/or physicochemical data have been disclosed in the medicinal chemistry literature for these inhibitors and their close analogues. Results: The compiled data are analyzed primarily focusing on the pharmacokinetic or toxicological deficiencies found in lead compounds and the structural modification strategies used to generate candidate compounds. Conclusion: The structure-property relationships hereby summarized how the overall druglike properties could be successfully improved by modifying the structure of protease inhibitors. These specific examples are expected to serve as useful references and guidance for developing new protease inhibitor drugs in the future.Keywords
Funding Information
- National Research Foundation of Korea (NRF) by the Korea Government (2020R1F1A1073097)
This publication has 120 references indexed in Scilit:
- Into the Fray! A Beginner's Guide to Medicinal ChemistryChemMedChem, 2021
- Discovery of Voxilaprevir (GS-9857): The Pan-Genotypic Hepatitis C Virus NS3/4A Protease Inhibitor Utilized as a Component of Vosevi®2019
- Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 InfectionDrugs, 2015
- Tactics in Contemporary Drug Design2015
- Global distribution and prevalence of hepatitis C virus genotypesHepatology, 2014
- High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injuryHepatology, 2012
- Oral, Direct Thrombin and Factor Xa Inhibitors: The Replacement for Warfarin, Leeches, and Pig Intestines?Angewandte Chemie International Edition, 2011
- Induced‐Fit Binding of the Macrocyclic Noncovalent Inhibitor TMC435 to its HCV NS3/NS4A Protease TargetAngewandte Chemie International Edition, 2010
- Optimization of metabolic stability as a goal of modern drug designMedicinal Research Reviews, 2001
- The Behavior and Significance of Slow‐Binding Enzyme Inhibitors1988